Profile data is unavailable for this security.
About the company
AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.
- Revenue in USD (TTM)44.04bn
- Net income in USD-1.25bn
- Incorporated1992
- Employees83.10k
- LocationAstraZeneca PLC1 Francis Crick AvenueCAMBRIDGE CB2 0AAUnited KingdomGBR
- Phone+44 207 304 5000
- Fax+44 207 604 8151
- Websitehttps://www.astrazeneca.com/Home
Mergers & acquisitions
| Acquired company | AZN:LSE since announced | Transaction value |
|---|---|---|
| TeneoTwo Inc | 1.79% | 1.27bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen, Inc. | 26.38bn | 6.58bn | 132.86bn | 24.20k | 21.36 | 55.74 | 13.56 | 5.11 | 11.80 | 11.80 | 47.50 | 4.52 | 0.4432 | 1.48 | 5.38 | 1,090,248.00 | 11.05 | 11.07 | 14.32 | 13.40 | 75.75 | 79.29 | 24.92 | 30.88 | 1.17 | 7.46 | 0.9379 | 49.28 | 2.18 | 2.47 | -18.87 | -5.26 | 1.01 | 11.97 |
| Bristol-Myers Squibb Co | 47.14bn | 6.62bn | 160.06bn | 32.20k | 24.88 | 4.90 | 9.34 | 3.39 | 3.01 | 3.01 | 21.49 | 15.27 | 0.4465 | 4.58 | 6.00 | 1,464,099.00 | 6.29 | 2.67 | 7.76 | 3.29 | 79.22 | 74.18 | 14.08 | 6.54 | 1.34 | 5.55 | 0.5629 | 163.84 | 9.09 | 19.01 | 177.58 | 9.43 | -4.35 | 5.22 |
| AstraZeneca plc (ADR) | 44.04bn | -1.25bn | 202.87bn | 83.10k | -- | 5.72 | 31.65 | 4.60 | -0.425 | -0.425 | 14.28 | 11.59 | 0.5174 | 2.02 | 5.77 | 529,939.80 | -1.47 | 2.62 | -1.98 | 3.66 | 74.85 | 78.90 | -2.84 | 6.61 | 0.6737 | 5.85 | 0.451 | 196.26 | 40.58 | 10.22 | -96.50 | -49.76 | -1.01 | -- |
| Merck & Co., Inc. | 57.17bn | 16.64bn | 226.78bn | 68.00k | 13.60 | 5.22 | 11.13 | 3.95 | 6.56 | 6.53 | 22.53 | 17.07 | 0.5781 | 3.03 | 6.54 | 840,720.60 | 16.84 | 7.61 | 21.83 | 10.14 | 70.77 | 70.92 | 29.13 | 16.06 | 1.15 | 21.89 | 0.4223 | 86.06 | 17.31 | 4.12 | 173.18 | 25.79 | 22.48 | 7.49 |
| AbbVie Inc | 57.35bn | 12.57bn | 247.98bn | 50.00k | 19.93 | 17.01 | 11.92 | 4.35 | 7.07 | 7.07 | 32.27 | 8.29 | 0.3939 | 4.95 | 5.42 | 1,146,980.00 | 8.69 | 7.46 | 11.10 | 9.46 | 70.72 | 72.03 | 22.05 | 18.11 | 0.7456 | 8.27 | 0.8324 | 97.89 | 22.69 | 16.99 | 151.71 | 14.13 | 10.44 | 17.93 |
| Pfizer Inc. | 101.13bn | 29.75bn | 279.31bn | 79.00k | 9.63 | -- | 8.14 | 2.77 | 5.19 | 5.11 | 17.62 | -- | -- | -- | -- | 1,280,152.00 | -- | 6.62 | -- | 8.25 | 62.21 | 74.04 | 29.44 | 21.32 | -- | 22.12 | -- | 75.72 | 95.16 | 9.00 | 238.05 | 25.51 | 6.28 | 5.39 |
| Eli Lilly And Co | 29.07bn | 5.69bn | 287.92bn | 35.00k | 48.61 | 33.87 | 39.63 | 9.96 | 6.27 | 6.27 | 32.02 | 8.99 | 0.6128 | 1.81 | 4.77 | 830,591.40 | 12.00 | 11.08 | 17.83 | 15.80 | 75.98 | 77.16 | 19.58 | 20.77 | 0.846 | 7.33 | 0.6601 | 53.75 | 15.40 | 5.94 | -9.88 | 15.31 | 11.40 | 10.76 |
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2022 | 94.23m | 3.04% |
| Wellington Management Co. LLPas of 31 Mar 2022 | 46.69m | 1.51% |
| PRIMECAP Management Co.as of 30 Jun 2022 | 45.81m | 1.48% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2022 | 36.99m | 1.19% |
| Fisher Asset Management LLCas of 30 Jun 2022 | 21.39m | 0.69% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2022 | 18.92m | 0.61% |
| GQG Partners LLCas of 31 Mar 2022 | 18.28m | 0.59% |
| Franklin Advisers, Inc.as of 30 Jun 2022 | 14.85m | 0.48% |
| CIBC Private Wealth Advisors, Inc.as of 30 Jun 2022 | 10.73m | 0.35% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 9.31m | 0.30% |
